Oral anti-inflammatory composition as well as preparation method and application thereof

The problem of adhesion and stability of sodium oxysulfonate in oral care compositions is solved by using anti-inflammatory compositions of sodium oxysulfonate, catechin and saponin in oral care compositions, combining vitamin B3 and chitosan. , achieves long-lasting anti-inflammatory and antibacterial protection, and promotes the repair and healing of oral mucosa.

CN118987066APending Publication Date: 2024-11-22SHANDONG HUASU PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411160690.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Sodium oxysulfonate has insufficient adhesion in oral wet environment, short residence time and poor stability, which affects its therapeutic effect and is not ideal for bioavailability, and its performance in oral care compositions needs to be improved.

Method used

Using an anti-inflammatory composition containing sodium oxysulfonate, catechin and saponin, combined with vitamin B3 and chitosan, thickeners, sweeteners and preservatives, to improve adhesion through specific formulation regulators and Stability, forming a stable adhesion layer, enhancing anti-inflammatory and antibacterial effects, and promoting local blood circulation and cell repair.

Benefits of technology

It significantly improves the residence time and stability of sodium hyaluronate in the oral cavity, enhances the anti-inflammatory and antibacterial effects, promotes tissue repair and healing of oral mucosa, and improves bioavailability and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005006318740000101
    Figure BDA0005006318740000101
  • Figure BDA0005006318740000111
    Figure BDA0005006318740000111
  • Figure BDA0005006318740000131
    Figure BDA0005006318740000131
Patent Text Reader

Abstract

The invention provides an oral anti-inflammatory composition which comprises an anti-inflammatory component, an auxiliary functional component and a formula regulator, and the anti-inflammatory component is a combination of sodium gualenate, catechin and pseudo-ginseng saponin; the auxiliary functional components comprise vitamin B3 and chitosan; the formula regulator comprises a thickening agent, a sweetening agent, a preservative and a filling agent. On one hand, the oral anti-inflammatory composition can improve the stability of sodium gualenate in an oral environment, and on the other hand, the retention time of the medicine in an oral mucosa is prolonged to form a stable adhesion layer, so that the anti-inflammatory effect and the broad-spectrum antibacterial effect are further enhanced; and the special components in the composition also have the effects of regenerating and repairing cells and promoting local blood circulation, are beneficial to accelerating tissue repair of oral mucosa at an inflammation part, and promote wound healing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of oral care, and in particular to an oral anti-inflammatory composition and a preparation method and application thereof. Background Art

[0002] Oral inflammation, including periodontitis, gingivitis, etc., is a common disease that affects human health. Treatment of these inflammations usually relies on the use of anti-inflammatory drugs to alleviate symptoms and prevent disease progression. Various anti-inflammatory ingredients are widely used in traditional oral care compositions in order to achieve therapeutic effects.

[0003] As an effective anti-inflammatory ingredient, sodium azulene sulfonate shows significant therapeutic effects in oral care compositions. It has multiple pharmacological effects of anti-inflammatory, antibacterial and anti-allergic effects, can effectively reduce oral inflammatory reactions, inhibit the release of inflammatory mediators, and is of great significance for improving oral hygiene and treating oral diseases. Compared with other anti-inflammatory drugs, sodium azulene sulfonate has the advantages of multi-effects, safety and targeting, and is particularly suitable for the oral environment. It can play a role against common oral pathogens and reduce the number of harmful bacteria.

[0004] However, although sodium azulene sulfonate has significant therapeutic effects, there are still some shortcomings in practical applications, which limit its performance in oral care compositions. In the moist environment of the oral cavity, the adhesion of sodium azulene sulfonate is insufficient, resulting in a shorter residence time on the oral mucosa, which affects the sustained action and efficacy of the drug. In addition, in the complex biochemical environment of the oral cavity, sodium azulene sulfonate may be affected by factors such as pH changes and enzymolysis, and its stability needs to be improved. Due to the limitations of solubility and membrane permeability, the bioavailability of sodium azulene sulfonate is not ideal and needs to be further improved through formulation technology.

[0005] Therefore, developing a novel oral care composition to improve the adhesion and stability of sodium azulene sulfonate and increase its bioavailability in the oral cavity has become a technical demand in the field of oral care. The ideal composition should be able to provide long-lasting and effective anti-inflammatory and antibacterial protection while ensuring safety and comfort. Summary of the invention

[0006] In order to solve the problems in the prior art, the present invention forms a specific anti-inflammatory composition containing sodium azulene sulfonate, which can improve the stability of sodium azulene sulfonate in the oral environment on the one hand, and increase the residence time of the drug in the oral mucosa on the other hand to form a stable adhesion layer, thereby further enhancing the anti-inflammatory effect and broad-spectrum antibacterial efficacy. In addition, the unique ingredients in the composition also have cell regeneration and repair effects and the effect of promoting local blood circulation, which is beneficial to accelerate tissue repair of the oral mucosa at the inflamed site and promote wound healing.

[0007] The first aspect of the present invention provides an oral anti-inflammatory composition, comprising an anti-inflammatory component, an auxiliary functional component and a formula regulator, wherein:

[0008] The anti-inflammatory ingredients are a combination of sodium azulene sulfonate, catechins and notoginseng saponins;

[0009] Auxiliary ingredients include vitamin B3 and chitosan;

[0010] Formulation modifiers include thickeners, sweeteners, preservatives and fillers.

[0011] In a preferred embodiment, the content of each component is as follows based on the weight of the oral anti-inflammatory composition:

[0012] Sodium azulene sulfonate: 1%-10%;

[0013] Catechins: 0.5%-2%;

[0014] Panax notoginseng saponin: 0.5%-3%;

[0015] Vitamin B3: 0.2%-1%;

[0016] Chitosan: 0.5%-5%;

[0017] Thickener: 0.5%-5%;

[0018] Sweetener: 0.1%-1%;

[0019] Preservatives: 0.01%-0.5%;

[0020] The balance is filler.

[0021] Further preferably, in one embodiment, the content of each component is as follows based on the weight of the oral anti-inflammatory composition:

[0022] Sodium azulene sulfonate: 1.5%-5%;

[0023] Epigallocatechin gallate-3-O-galactoside (EGCG): 0.8%-1.5%;

[0024] Panax notoginseng saponin: 1%-2%;

[0025] Vitamin B3: 0.4%-0.6%;

[0026] Chitosan: 1%-4%;

[0027] Thickener: 1%-3%;

[0028] Sweetener: 0.2%-0.5%;

[0029] Preservatives: 0.05%-0.2%;

[0030] The balance is filler.

[0031] In some preferred embodiments, the thickener includes but is not limited to one or more of xanthan gum, sodium carboxymethyl cellulose, guar gum, gum arabic, and hydroxyethyl cellulose.

[0032] In some preferred embodiments, the sweetener includes but is not limited to one or more of aspartame, sucralose, cyclamate, saccharin sodium, and xylitol.

[0033] In some preferred embodiments, the preservative includes, but is not limited to, one or more of p-hydroxybenzoic acid esters, phenoxyethanol, dehydroacetic acid, and sodium diacetate.

[0034] In some preferred embodiments, the filler includes but is not limited to one or more of microcrystalline cellulose, silicate, starch, and lactose.

[0035] A second aspect of the present invention provides a method for preparing an oral anti-inflammatory composition, comprising:

[0036] a. Dissolve sodium azulene sulfonate, catechins, notoginseng saponins and vitamin B3 in deionized water at 30-50°C;

[0037] b. Add chitosan and stir until the chitosan is completely dissolved. After cooling to room temperature, add thickener, sweetener and preservative and stir thoroughly until evenly mixed.

[0038] The third aspect of the present invention also provides a method for preparing an oral anti-inflammatory composition patch, and based on the composition obtained by the method for preparing the oral anti-inflammatory composition, the following steps are further included:

[0039] a. freeze-drying the resulting uniformly mixed solution to remove moisture therefrom and form a dry powdery substance;

[0040] b. Mixing the dried powder with a lubricant and a binder;

[0041] c. Use a tablet press to make tablets and finally make patches.

[0042] The fourth aspect of the present invention also provides a use of the oral anti-inflammatory composition as described in the first aspect in eliminating inflammation and repairing oral mucosa.

[0043] The oral anti-inflammatory composition, preparation method and application provided by the present invention have the following beneficial effects:

[0044] (1) By adding sodium azulene sulfonate, catechins and notoginseng saponins as anti-inflammatory ingredients, the three work synergistically to enhance the anti-inflammatory effect. The synergistic effect of sodium azulene sulfonate, catechins and notoginseng saponins in anti-inflammatory effects is mainly reflected in the complementarity of their mechanisms of action. Sodium azulene sulfonate directly reduces the inflammatory response by inhibiting the release of inflammatory mediators; catechins, especially EGCG, as a powerful antioxidant, can block the generation of free radicals, reduce oxidative stress, and thus inhibit the activation of inflammatory pathways; notoginseng saponins accelerate metabolism and repair in the inflammatory area by promoting blood circulation, and they themselves also have anti-inflammatory effects. The combination of these three not only reduces the generation of inflammatory mediators from the source, but also improves the nutrient supply in the inflammatory area by promoting local blood circulation, acting together on different links of the inflammatory process to achieve an enhanced anti-inflammatory effect.

[0045] (2) The addition of chitosan can increase the residence time of drugs on the oral mucosa, and experiments have shown that catechins and Panax notoginseng saponins may have a synergistic effect with chitosan to form a more stable adhesion layer, further enhancing the drug delivery efficiency.

[0046] (3) The added vitamin B3 promotes cell regeneration and repair, while the blood-activating and blood-stasis-removing effects of Panax notoginseng saponins promote local blood circulation and accelerate tissue repair.

[0047] (4) The added tea catechins are a natural antioxidant that can neutralize free radicals and reduce oxidative stress. It not only inhibits the activation of inflammatory pathways, but also has a positive effect on the sustained stability of sodium azulene sulfonate in the oral environment, reducing the side effects of sodium azulene sulfonate and achieving a lasting anti-inflammatory effect.

[0048] (5) The addition of thickeners, sweeteners and preservatives can improve the taste and stability of the product. Good taste and comfort can increase patient acceptance. DETAILED DESCRIPTION

[0049] In order to better understand the above technical solution, the above technical solution will be described in detail below in combination with specific implementation methods.

[0050] In a first aspect, the present invention provides an oral anti-inflammatory composition, comprising an anti-inflammatory component, an auxiliary functional component and a formula regulator, wherein:

[0051] The anti-inflammatory ingredients are a combination of sodium azulene sulfonate, catechins and notoginseng saponins;

[0052] Auxiliary ingredients include vitamin B3 and chitosan;

[0053] Formulation modifiers include thickeners, sweeteners, preservatives and fillers.

[0054] The ingredients in the oral anti-inflammatory composition can be divided into three categories from the perspective of functionality. Since the main purpose of the present invention is anti-inflammatory, anti-inflammatory ingredients are essential ingredients of the present invention. Sodium azulene sulfonate, catechins and notoginseng saponins are the core anti-inflammatory ingredients of the oral anti-inflammatory composition of the present invention, each of which has a unique pharmacological effect and can work synergistically to enhance the overall anti-inflammatory effect.

[0055] Sodium azulene sulfonate is a known anti-inflammatory agent that is widely used in clinical applications to treat various inflammatory diseases, including oral inflammation. Due to its inhibitory effect on inflammatory mediators, it can effectively reduce inflammatory responses. Therefore, sodium azulene sulfonate is used as an effective anti-inflammatory ingredient in oral care products to help relieve the symptoms of oral diseases such as gingivitis and periodontitis.

[0056] Catechins are a class of polyphenolic compounds found in green tea that have powerful antioxidant and anti-inflammatory properties. Among them, epicatechin gallate (EGCG) is one of the most widely studied and most active catechins. Catechins are mainly obtained from green tea leaves by water extraction, and the extraction process includes hot water soaking, filtration and concentration. Catechins such as EGCG exert anti-inflammatory effects by inhibiting multiple inflammatory pathways, such as reducing the expression of pro-inflammatory cytokines and blocking the NF-κB signaling pathway. In addition, catechins also have antibacterial and antiviral activities, which help maintain oral health.

[0057] Panax notoginseng saponins are active ingredients extracted from the traditional Chinese medicine Panax notoginseng (scientific name: Panax notoginseng), which have anti-inflammatory, anti-coagulant and blood circulation promoting effects. In oral anti-inflammatory compositions, Panax notoginseng saponins help reduce swelling and pain while promoting the repair and healing of damaged tissues.

[0058] The combination of these three not only reduces the generation of inflammatory mediators from the source, but also improves the nutrient supply in the inflammatory area by promoting local blood circulation, acting together on different links of the inflammatory process to enhance the anti-inflammatory effect. The added tea catechins, a natural antioxidant, can neutralize free radicals and reduce oxidative stress. It not only inhibits the activation of inflammatory pathways, but also has a positive effect on the continued stability of sodium azulene sulfonate in the oral environment, reducing the side effects of sodium azulene sulfonate and achieving a lasting anti-inflammatory effect.

[0059] In the selection of specific contents of the composition, based on the consideration of anti-inflammatory synergistic effect, the sodium azulene sulfonate is 1%-10%, preferably 1.5%-5%, by weight of the oral anti-inflammatory composition; the catechins are listed as epicatechin, epicatechin gallate (EGC), epicatechin gallate-3-O-galactoside (EGCG), catechin gallate (GC), catechin gallate-3-O-galactoside (GCG), among which epicatechin gallate-3-O-galactoside (EGCG) is preferred, and the content of catechins is 0.5%-2%, preferably 0.8%-1.5%, by weight of the oral anti-inflammatory composition; the content of Panax notoginseng saponin is 0.5%-3%, preferably 1%-2%.

[0060] The second type of ingredients in the oral anti-inflammatory composition are auxiliary functional ingredients, mainly including vitamin B3 and chitosan. Vitamin B3, also known as nicotinamide or niacin, is a water-soluble vitamin that has a significant effect on promoting cell regeneration and repair. It participates in the metabolic process of cells and helps maintain the health of the skin and mucous membranes, which is particularly important for damaged oral mucosa. In addition, vitamin B3 also helps to regulate immune responses and balance the microbial environment in the oral cavity, thereby indirectly supporting the efficacy of anti-inflammatory ingredients. The blood-activating and blood-stasis-removing effects of Panax notoginseng saponins are combined with vitamin B3 to promote local blood circulation, accelerate tissue repair, and jointly provide support for oral health. Based on the weight of the oral anti-inflammatory composition, vitamin B3 is 0.2%-1%, preferably 0.4%-0.6%.

[0061] The role of chitosan in the oral anti-inflammatory composition is reflected in its improvement of drug delivery efficiency. The addition of chitosan not only increases the residence time of the drug on the oral mucosa, but also experiments show that it may have a synergistic effect with catechins and Panax notoginseng saponins to form a more stable adhesion layer. This adhesion layer enhances the delivery efficiency of the drug, allowing the anti-inflammatory ingredients to act more effectively on the site of inflammation. The film-forming properties of chitosan provide protection for the oral mucosa and reduce external stimuli. At the same time, its natural antibacterial properties help inhibit the growth of oral pathogens and maintain the hygiene of the oral environment. Based on the weight of the oral anti-inflammatory composition, chitosan is 0.5%-5%, preferably 1%-4%.

[0062] The third type of ingredients in the oral anti-inflammatory composition are formula regulators, which are mainly added to the patch molding for taste, shelf life, filling and disintegration, and mainly include thickeners, sweeteners, preservatives and fillers, among which:

[0063] Thickeners are used in oral anti-inflammatory compositions to adjust the viscosity of the product to improve its distribution and retention time in the oral cavity, thereby increasing the efficacy of the composition. Thickeners include, but are not limited to, one or more of xanthan gum, sodium carboxymethyl cellulose, guar gum, gum arabic, and hydroxyethyl cellulose. The content of the thickeners is 0.5%-5%, preferably 1%-3%, based on the weight of the oral anti-inflammatory composition.

[0064] Sweeteners are used to mask the bitterness or other unpleasant taste of the drug and improve the patient's acceptance and compliance when using it, including but not limited to one or more of aspartame, sucralose, cyclamate, saccharin sodium, and xylitol; based on the weight of the oral anti-inflammatory composition, the content is 0.1%-1%, preferably 0.2%-0.5%.

[0065] The function of the preservative is to inhibit the growth of microorganisms and ensure the stability and safety of the oral anti-inflammatory composition during storage and use. The preservative includes, but is not limited to, one or more of parabens, phenoxyethanol, dehydroacetic acid, and sodium diacetate. The content is 0.01%-0.5%, preferably 0.05%-0.2%, based on the weight of the oral anti-inflammatory composition.

[0066] Fillers are used to adjust the volume and physical form of the composition, and sometimes also act as stabilizers to ensure that other ingredients are evenly dispersed, including but not limited to one or more of microcrystalline cellulose, silicates, starch, and lactose, with a content of 75%-95%, preferably 85%-90%, based on the weight of the oral anti-inflammatory composition.

[0067] A second aspect of the present invention provides a method for preparing an oral anti-inflammatory composition, comprising:

[0068] a. Dissolve sodium azulene sulfonate, catechins, notoginseng saponins and vitamin B3 in deionized water at 30-50°C;

[0069] b. Add chitosan and stir until the chitosan is completely dissolved. After cooling to room temperature, add thickener, sweetener and preservative and stir thoroughly until evenly mixed.

[0070] Dissolving the main active ingredient first and then adding auxiliary ingredients and other additives helps each ingredient to be evenly mixed and ensures that each ingredient can perform its function in the final product. Using deionized water at 30-50°C as a solvent helps to increase the dissolution rate and ensure that the active ingredient can be dissolved faster and more completely, while avoiding excessively high water temperature that may cause side reactions of sodium azulene sulfonate and reduce drug activity.

[0071] The third aspect of the present invention also provides a method for preparing an oral anti-inflammatory composition patch, and based on the composition obtained by the method for preparing the oral anti-inflammatory composition, the following steps are further included:

[0072] a. freeze-drying the resulting uniformly mixed solution to remove moisture therefrom and form a dry powdery substance;

[0073] b. Mix the dried powder with an appropriate amount of lubricant and binder;

[0074] c. Use a tablet press to make tablets and finally make patches.

[0075] Freeze drying is a technique used to remove water from a homogenous mixed solution while maintaining the stability and biological activity of the active ingredients. During the freeze drying process, the solution is first frozen into a solid state, and then the ice crystals are removed by sublimation, leaving behind a dry powdery substance.

[0076] The lubricant added in this process ensures that the tableting process proceeds smoothly. The lubricant helps prevent the powder from adhering to the equipment, while ensuring the smooth surface of the patch, improving the appearance and quality of the finished product. The main lubricants include but are not limited to one or more of microcrystalline cellulose, talc, magnesium stearate, and polyethylene glycol, and the content is preferably an amount that can achieve a lubricating effect in tableting in the art.

[0077] The binder forms a bond between the powder particles, enhances the mechanical strength and stability of the patch, promotes the flow and uniform distribution of the powder, and ensures the consistency and uniformity of the components in the patch. The main binder components include, but are not limited to, one or more of sodium carboxymethylcellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, gelatin, and gum arabic, and the content is preferably an amount that can achieve a bonding effect in tableting in the art.

[0078] After the dry powder is mixed with a lubricant and an adhesive, a tablet press is used to press the powder into a patch. This process involves compressing the powder into a sheet-like solid dosage form with a certain shape, size and thickness. Tableting can not only improve the physical form of the drug, but also improve its stability and portability. The preferred patch diameter of the present invention is 2-4mm, and the circular patch with a thickness of 0.5-1.5mm ensures that the contact with the oral mucosa is maximized. The patch of the present invention is mainly a drug layer, and according to actual needs, a backing layer and an adhesive layer conventional in the art can also be included to ensure mechanical strength and adhesion under the oral mucosa and a moist environment.

[0079] The fourth aspect of the present invention also provides an application of the oral anti-inflammatory composition as described in the first aspect in eliminating inflammation and repairing oral mucosa. The oral anti-inflammatory composition of the present invention can be directly applied to the area of ​​oral mucosa affected by inflammation. By placing a patch formed by the composition in the oral cavity, it is gradually dissolved in the inflamed area, releasing effective ingredients such as sodium azulene sulfonate, catechins, and panax notoginseng saponins, playing an anti-inflammatory and repair-promoting role, relieving pain and promoting the healing of damaged mucosa.

[0080] The following will clearly and completely describe the present application scheme in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.

[0081] Examples 1-3 are oral anti-inflammatory composition formulations as shown in Table 1:

[0082] Table 1 Example formulation:

[0083]

[0084] The preparation methods of Examples 1-3 are as follows:

[0085] Dissolve sodium azulene sulfonate, catechin, notoginseng saponin and vitamin B3 according to the measured amounts in Table 1 with deionized water at 30-50°C;

[0086] b. Add the corresponding measured amount of chitosan in Table 1, and stir until the chitosan is completely dissolved. After cooling to room temperature, add the corresponding specific types and measured amounts of thickeners, sweeteners and preservatives in Table 1, and stir until evenly mixed.

[0087] Example 4

[0088] The mixed solution of the composition obtained in Example 1 was freeze-dried at a temperature of -60°C to remove moisture and form a dry powdery substance;

[0089] The dried powder (about 100 g) was mixed with 3 g of microcrystalline cellulose and 5 g of sodium carboxymethyl cellulose, and tableted using a tablet press to form a patch with a uniform diameter of 3±0.2 mm and a thickness of 1±0.1 mm. The weight of the prepared patch was 10±0.5 mg.

[0090] Example 5

[0091] According to the method of Example 4, a patch of the same specifications as Example 2 was prepared.

[0092] Example 6

[0093] According to the method of Example 6, a patch of the same specifications as Example 3 was prepared.

[0094] Comparative Examples 1-7 are the formulas of the control group of oral anti-inflammatory compositions, as shown in Table 2:

[0095] Table 2 Comparative Example Formula:

[0096]

[0097] The preparation method of Comparative Examples 1-7 is the same as that of Examples 1-3, except that the measured amounts of the components are different.

[0098] Comparative Examples 8-14 are the preparation methods of the patches of Comparative Examples 1-7, respectively. The compositions obtained in Comparative Examples 1-7 are used to prepare patches of the same specifications according to the method of Example 4.

[0099] Experimental Example 1: Clinical trial of oral anti-inflammatory composition patch on oral ulcers

[0100] 1. Test materials: oral anti-inflammatory composition patches obtained in Examples 4-6 and Comparative Examples 8-14.

[0101] 2. Experimental subjects: 500 patients with recurrent aphthous ulcer (RAU) aged 20-65 were selected and randomly divided into an embodiment group and a comparative example group, with 50 patients in each embodiment and comparative example group for the experiment.

[0102] 3. Trial criteria: The subjects were healthy adult males and females who met the inclusion and exclusion criteria.

[0103] 3.1. Inclusion criteria: good general health, with a history of RAU but no systemic diseases; able to read, understand and sign the informed consent form, able to record according to the requirements of the trial and participate in the examination at any time during the trial; at least one oral ulcer in the mouth and the ulcer occurred within 48 hours; no allergy to the patch and its ingredients; no use of other drugs for the treatment of oral ulcers; no participation in other similar experimental studies before the test.

[0104] 3.2. Exclusion criteria: severe recurrent aphthous ulcer, Behcet's disease; systemic disease background such as anemia, peptic ulcer, Crohn's disease, acute infectious diseases, autoimmune diseases, etc.; use of analgesics or oral ulcer treatment drugs within 24 hours; use of antibiotics and anti-inflammatory drugs within 1 month, systemic use of corticosteroids and immunosuppressants within 3 months; smokers and alcoholics within 3 months; cancer patients; history of allergy to oral health products or their ingredients; women who are pregnant or lactating.

[0105] 4. Evaluation indicators:

[0106] 4.1. Average ulcer duration (days, D): the sum of the duration of ulcers during the evaluation period divided by the total number of ulcers.

[0107] 4.2 Pain index (points, P): The visual analogue scale (VAS) was used to record the pain score every day during the ulcer period. VAS was expressed using a 10 cm straight line, with the 0 end of the straight line representing "no pain" and the 10 cm end representing "the most severe pain". Subjects recorded the pain on the corresponding scale of the straight line once a day according to the degree of pain they felt.

[0108] Evaluation index classification: D1: shortened average ulcer period (t test, P < 0.05); D0: change in average ulcer period (t test, P > 0.05); P1: decreased pain index (t test, P < 0.05); P0: no change in pain index (t test, P > 0.05). Evaluation criteria: markedly effective (D1P1); effective (D1P0 or D0P1); ineffective (D0P0).

[0109] 5. Test methods:

[0110] Teach the patients to record the pain index, give them the "Oral Ulcer Record Form", record the contact number of the subjects, distribute the patches of the embodiment and comparative example, and place the patches on a clean finger 10 minutes after rinsing the mouth after three meals, and press them on the ulcer surface, three times a day. Then, make a telephone return visit to the subjects every day to understand the development of the ulcer. After the oral ulcer heals, perform an oral examination and collect the "Oral Ulcer Record Form". The experiment was completed using a double-blind method.

[0111] Test results:

[0112] The test results are shown in Tables 3 and 4.

[0113] Table 3 Pain index test data:

[0114]

[0115] The pain reflects the inflammation. As shown in Table 3, the tablets of Examples 4-6 prepared by using the oral anti-inflammatory composition of Examples 1-3 provided by the present invention can significantly (P < 0.1) reduce the pain of patients with oral ulcers, and have an inflammation-inhibiting effect on oral ulcers. However, when the patch lacking sodium azulene sulfonate, catechins and one of notoginseng saponins is used for treatment (Comparative Examples 8-10), the effect of inflammation inhibition is generally worse, and in the group of tests without vitamin B3 and chitosan (Comparative Examples 11-12), the pain is also stronger. Even if all three anti-inflammatory components are present, the effect is not as good as that of the embodiment when the content of catechins is low. It is proved that the composition of the present invention has obvious effect in anti-inflammatory synergy.

[0116] Table 4 Ulcer healing time test data

[0117]

[0118]

[0119] As shown in Table 4, the tablets of Examples 4-6 prepared by using the oral anti-inflammatory composition of Examples 1-3 can significantly (P < 0.05) shorten the ulcer time of patients with oral ulcers and help oral cells to repair quickly. When the patch lacking sodium azulene sulfonate, catechins and one of notoginseng saponins is used for treatment (Comparative Examples 8-10), the effect on cell repair is generally worse, and in the group of tests without vitamin B3 and chitosan (Comparative Examples 11-12), the ulcer cycle is also longer. Even if all three anti-inflammatory components are present, the effect is not as good as in the examples when the content of catechins is low. It is proved that the composition of the present invention has a significant synergistic effect in cell repair.

[0120] Although the present invention has been described to a certain extent, it is obvious that appropriate changes in various conditions can be made without departing from the spirit and scope of the present invention. It is understood that the present invention is not limited to the embodiments described, but belongs to the scope of the claims, which includes equivalent replacements of each factor described.

Claims

1. An oral anti-inflammatory composition, characterized in that: Contains anti-inflammatory ingredients, auxiliary ingredients and formula regulators, including: The anti-inflammatory ingredients are a combination of sodium azulene sulfonate, catechins and notoginseng saponins; Auxiliary ingredients include vitamin B3 and chitosan; Formulation modifiers include thickeners, sweeteners, preservatives and fillers.

2. The oral anti-inflammatory composition according to claim 1, characterized in that Based on the weight of the oral anti-inflammatory composition, the contents of each component are as follows: Sodium azulene sulfonate: 1%-10%; Catechins: 0.5%-2%; Panax notoginseng saponin: 0.5%-3%; Vitamin B3: 0.2%-1%; Chitosan: 0.5%-5%; Thickener: 0.5%-5%; Sweetener: 0.1%-1%; Preservatives: 0.01%-0.5%; The balance is filler.

3. The oral anti-inflammatory composition according to claim 2, characterized in that Based on the weight of the oral anti-inflammatory composition, the contents of each component are as follows: Sodium azulene sulfonate: 1.5%-5%; Epicatechin gallate-3-O-galactoside: 0.8%-1.5%; Panax notoginseng saponin: 1%-2%; Vitamin B3: 0.4%-0.6%; Chitosan: 1%-4%; Thickener: 1%-3%; Sweetener: 0.2%-0.5%; Preservatives: 0.05%-0.2%; The balance is filler.

4. The oral anti-inflammatory composition according to claim 1, characterized in that The thickener is but not limited to one or more of xanthan gum, sodium carboxymethyl cellulose, guar gum, gum arabic, and hydroxyethyl cellulose; and / or The sweetener includes but is not limited to one or more of aspartame, sucralose, sodium cyclamate, saccharin sodium, and xylitol; and / or The preservatives include but are not limited to one or more of parabens, phenoxyethanol, dehydroacetic acid, and sodium diacetate; and / or The filler includes, but is not limited to, one or more of microcrystalline cellulose, silicate, starch, and lactose.

5. The method for preparing an oral anti-inflammatory composition according to claim 1, characterized in that: The steps include: a. Dissolve sodium azulene sulfonate, catechins, notoginseng saponins and vitamin B3 in deionized water at 30-50°C; b. Add chitosan and stir until the chitosan is completely dissolved. After cooling to room temperature, add thickener, sweetener and preservative and stir thoroughly until evenly mixed.

6. A method for preparing an oral anti-inflammatory composition patch, characterized in that: Based on the preparation method of the oral anti-inflammatory composition according to claim 5, the method further comprises the following steps: a. freeze-drying the resulting uniformly mixed solution to remove moisture therefrom and form a dry powdery substance; b. Mixing the dried powder with a lubricant and a binder; c. Use a tablet press to compress the tablets and finally make a patch.

7. Use of the oral anti-inflammatory composition according to claim 1 in eliminating inflammation and repairing oral mucosa.